Search results
Results from the WOW.Com Content Network
The Code Breaker: Jennifer Doudna, Gene Editing, and the Future of the Human Race is a non-fiction book authored by American historian and journalist Walter Isaacson. Published in March 2021 by Simon & Schuster , it is a biography of Jennifer Doudna , the winner of the 2020 Nobel Prize in Chemistry for her work on the CRISPR system of gene ...
You are free: to share – to copy, distribute and transmit the work; to remix – to adapt the work; Under the following conditions: attribution – You must give appropriate credit, provide a link to the license, and indicate if changes were made.
Cas9 (or "CRISPR-associated protein 9") is an enzyme that uses CRISPR sequences as a guide to recognize and open up specific strands of DNA that are complementary to the CRISPR sequence. Cas9 enzymes together with CRISPR sequences form the basis of a technology known as CRISPR-Cas9 that can be used to edit genes within living organisms.
[2] [3] [4] The Wall Street Journal's reviewer said the book has compiled "perhaps the most comprehensive case for the lab-leak theory currently available". [5] Columnist Michael Hiltzik wrote in the Los Angeles Times that the authors "place[d] a conspiracy theory between hardcovers to masquerade as sober scientific inquiry."
The Times of London gave a mixed review, calling the book a "formidably informative read" while also saying that it "runs out of steam towards the end and becomes a general statement of techno-optimism." [4] Vox criticized the book for not addressing the "root causes" of economic inequality that "worsens health crises."
He co-developed Multiplex Automated Genome Engineering (MAGE) and optimized CRISPR/Cas9, discovered by Jennifer Doudna and Emmanuelle Charpentier for engineering a variety of genomes ranging from yeast to human. [62] His laboratory's use of CRISPR in human induced pluripotent stem cells (hiPS) is the latest contender for precise gene therapy. [64]
Nirmatrelvir/ritonavir has been evaluated in the treatment of COVID‑19 in standard-risk individuals in the EPIC-SR trial. [51] [53] This study did not achieve its primary goal of reducing time to sustained alleviation of COVID‑19 symptoms (treatment: 13 days (95% CI 12–15 days); placebo: 13 days (95% CI 11–14 days)).
The CRISPR treatment for LCA10 (the most common variant of Leber congenital amaurosis which is the leading cause of inherited childhood blindness) modifies the patient's defective photoreceptor gene. In March 2020, the first patient volunteer in this US-based study, sponsored by Editas Medicine , was given a low-dose of the treatment to test ...